Scholarlink

Purpose <p>Metastatic castration-resistant prostate cancer (mCRPC) is bone-predominant, requiring objective imaging biomarkers to guide Ra-223 therapy. We evaluated overall metabolic bone volume (OMBV) and overall total bone uptake (OTBU) from bone SPECT/CT as prognostic markers in mCRPC patients treated with Ra-223.</p> Methods <p>Thirty mCRPC patients underwent pre-treatment planar and SPECT/CT bone scintigraphy, with OMBV and OTBU derived using GI-BONE software. Overall survival (OS) was the primary endpoint; progression-free survival (PFS) and time to symptomatic skeletal event (TTSE) were secondary. Receiver operating characteristic analysis (Youden index) defined cut-offs for OS and TTSE independently. Treatment response was classified by composite changes in OMBV, OTBU, and bone scan index. OS, OMBV, and OTBU were analyzed by univariate Cox regression as continuous and dichotomized variables.</p> Results <p>Baseline skeletal burden was substantial (median OMBV 1,191.21 cm<sup>3</sup> [IQR 93.80–1,948.01]; median OTBU 9,746.18 [1,280.01– 17,587.11]); 87% had extent of disease grade 3–4. Post-treatment imaging in 24 patients yielded 10 responders (42%) and 14 non-responders (58%), with responder mean OMBV and OTBU reductions of 57% and 68%. Dichotomized baseline OMBV (hazard ratio [HR] 6.0320, 95% confidence interval [CI] 1.6880–21.5546; <i>p</i> &lt; 0.001) and OTBU (HR 9.4492, 95% CI 2.0968–42.5826; <i>p</i> &lt; 0.001) were significant predictors of OS. OMBV and OTBU were not significantly associated with PFS or TTSE.</p> Conclusions <p>OMBV and OTBU from bone SPECT/CT may provide useful prognostic information in mCRPC patients undergoing Ra-223 therapy, offering objective quantification of skeletal tumor burden using widely available technology. Further validation in larger cohorts is warranted.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Quantitative bone SPECT/CT-derived tumor burden as a prognostic biomarker in metastatic castration-resistant prostate cancer treated with Ra-223

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月13日

查看全文
  • Yoshimitsu Fukushima,
  • Go Kimura,
  • Jun Akatsuka,
  • Yoshimitsu Honda,
  • Yujiro Nakaoka,
  • Hiromitsu Hayashi,
  • Shinichiro Kumita

摘要

Purpose

Metastatic castration-resistant prostate cancer (mCRPC) is bone-predominant, requiring objective imaging biomarkers to guide Ra-223 therapy. We evaluated overall metabolic bone volume (OMBV) and overall total bone uptake (OTBU) from bone SPECT/CT as prognostic markers in mCRPC patients treated with Ra-223.

Methods

Thirty mCRPC patients underwent pre-treatment planar and SPECT/CT bone scintigraphy, with OMBV and OTBU derived using GI-BONE software. Overall survival (OS) was the primary endpoint; progression-free survival (PFS) and time to symptomatic skeletal event (TTSE) were secondary. Receiver operating characteristic analysis (Youden index) defined cut-offs for OS and TTSE independently. Treatment response was classified by composite changes in OMBV, OTBU, and bone scan index. OS, OMBV, and OTBU were analyzed by univariate Cox regression as continuous and dichotomized variables.

Results

Baseline skeletal burden was substantial (median OMBV 1,191.21 cm3 [IQR 93.80–1,948.01]; median OTBU 9,746.18 [1,280.01– 17,587.11]); 87% had extent of disease grade 3–4. Post-treatment imaging in 24 patients yielded 10 responders (42%) and 14 non-responders (58%), with responder mean OMBV and OTBU reductions of 57% and 68%. Dichotomized baseline OMBV (hazard ratio [HR] 6.0320, 95% confidence interval [CI] 1.6880–21.5546; p < 0.001) and OTBU (HR 9.4492, 95% CI 2.0968–42.5826; p < 0.001) were significant predictors of OS. OMBV and OTBU were not significantly associated with PFS or TTSE.

Conclusions

OMBV and OTBU from bone SPECT/CT may provide useful prognostic information in mCRPC patients undergoing Ra-223 therapy, offering objective quantification of skeletal tumor burden using widely available technology. Further validation in larger cohorts is warranted.